BioXcel Corporation

At xBxBio, our vision is to redefine the landscape of healthcare by building a comprehensive, state-of-the-art software solution that seamlessly integrates biology, physics, chemistry, mathematics, artificial intelligence, machine learning, augmented reality, and virtual reality to accelerate drug discovery and research across the globe. Its xBxBio ™ platform will enable scientists to test far more variables faster than what is available today. We believe that we can improve the likelihood of success for compounds by 150% and that we can also reduce the cost of a typical 3 phase FDA clinical study by over $120 million, and shave 5 to 6 years off the process. Furthermore, we believe that development candidates with more optimized property profiles will have a higher probability of success in clinical development.

Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe that this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs. Potential to provide clinical benefit to patients in need. The proprietary drug development approach aims to leverage existing approved drugs and/or clinically evaluated product candidates. IGALMI is a trademark of BioXcel Therapeutics, Inc. The information provided on this site is intended for use by healthcare professionals practicing in the US.

Silexon is an AI technology company driven by the needs for innovation of biotechnology, with a focus on data, empowering life science research to gain a faster, more systematic, and deeper insights into life, health, and diseases, accelerating innovation and commercialization in the field of biotechnology, and addressing the healthcare needs that have yet to be fulfilled. Provides end-to-end solutions for nucleic acid drug design, nucleic acid molecule generation, and optimization, significantly improving key indicators of nucleic acid sequences. BDE is a highly intelligent R & D system based on the latest Artificial Intelligence (AI) technology and algorithm models specially trained with large-scale biological data.

Xellar Biosystems is a Wet Artificial Intelligence (AI) biotechnology company, combining machine learning and AI with large-scale wet-lab experiments, tackling the most challenging problem in modern drug discovery – harnessing the complexity of human biology to accelerate drug discovery and development.

neoX is a biotech company that combines artificial intelligence (AI) with biophysics for drug research and development. neoX focuses on the research and development of macromolecular drugs and multispecific drugs, especially in the field of immuno-oncology. It has developed a sophisticated platform for early discovery of therapeutics by characterizing protein-protein interactions (PPI). neoX has established cooperation with biomedical companies globally to accelerate drug R&D pipelines.

BioX is a start-up company that is focused on sensing, human-machine interaction and exoskeleton development. BioX is founded in Aalborg, Denmark in 2019 as a spin-off from Aalborg University. The product to be launched in fall 2020 is the BioX AAL-Band. The strong team behind BioX works with great passion and the mission to empower people. BioX was founded in 2019 as a spinout of Aalborg University.